Investor Relations

Home > Investor Relations > IR Library > Statements of Cash Flows (consolidated)

Statements of Cash Flows (consolidated)

(million yen) 
  FY2017
(2017/4/1-2018/3/31)
FY2018
(2018/4/1-2019/3/31)
Net cash provided by operating activities 19,230 19,002
Net cash used in investing activities 20,093 3,994
Net cash provided by (used in) financing activities 4,670 809
Effect of exchange rate changes on cash and cash equivalents 591 943
Net increase in cash and cash equivalents 4,399 15,141
Cash and cash equivalents at beginning of the year 7,112 11,511
Cash and cash equivalents at end of the year 11,511 26,652

Home > Investor Relations > IR Library > Statements of Cash Flows (consolidated)
© Copyright TOWA PHARMACEUTICAL CO.,LTD. All Rights Reserved.